MCL-1 BIM Heterodimer Antibody Detection for Cancer Therapy Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatment methods face challenges due to the heterogeneity of tumors and the lack of well-defined molecular targets, with existing biomarkers being insufficient for predicting patient responses to therapies, particularly in relation to apoptosis pathways.
Innovation Solution
Development of antibodies that specifically bind to the MCL-1 and BIM heterodimer, allowing for the detection of this heterodimer in tumor samples and determining a ratio to a reference value, which is predictive of a patient's sensitivity to cancer treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If JC-1 fluorescent dye is used to measure mitochondrial outer membrane permeabilization, then functional BH3 measurement can be obtained, but the fluorescent signaling measurements are inconsistent and unreliable
Solution Approach 1:
The patent replaces the functional BH3 measurement system (which uses JC-1 fluorescent dye to measure mitochondrial outer membrane permeabilization) with a direct protein level measurement system using antibodies. This substitution eliminates the unreliable fluorescent signaling measurements while obtaining accurate quantitative data on BH3-only protein levels that directly correlates with cancer cell sensitivity to apoptosis-inducing agents.
2Quantity of substance
If direct measurement of BH3-only protein levels is performed, then protein quantity data can be obtained, but changes in these levels are not consistently correlated with sensitivity to anti-cancer agents
Solution Approach 1:
The patent uses a composite measurement approach that combines multiple antibody-based detections: antibodies specific to individual BH3-only proteins (to measure their levels) and antibodies specific to heterodimers formed between BH3-only proteins and anti-apoptotic BCL-2 family proteins. This composite measurement system provides both the quantity of BH3-only proteins and their functional status in heterodimer complexes, creating a reliable predictive marker for treatment sensitivity.
3Loss of information
If combination of functional BH3 measurement with direct protein level measurement is attempted, then comprehensive data can be obtained, but the methodology is complicated and not suited for solid tumor or fixed specimens
Solution Approach 1:
The patent extracts and measures specific protein complexes (heterodimers of BH3-only proteins with anti-apoptotic BCL-2 family proteins) directly from solid tumor or fixed specimens using antibody-based methods. This extraction approach eliminates the need for complex combined functional and direct measurement systems, as the heterodimer detection directly provides both protein level and functional information in a single assay that is compatible with solid tumor and fixed tissue samples.
4Adaptability or versatility
If existing biomarkers are used for cancer therapy prediction, then some therapeutic guidance can be provided, but the biomarkers are insufficient for accurately predicting patient responses to targeted therapies
Solution Approach 1:
The patent develops a universal biomarker system based on heterodimer detection that can predict patient response to multiple different apoptosis-inducing targeted therapies. By measuring the levels of heterodimers formed between BH3-only proteins and anti-apoptotic BCL-2 family proteins, this single biomarker system provides versatile therapeutic guidance across different cancer types and treatment regimens, overcoming the limitations of existing single-purpose biomarkers.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies provide improved predictive testing for cancer treatment by directly measuring the MCL-1 and BIM heterodimer ratio, enabling more accurate assignment of therapies to patients likely to benefit, overcoming the limitations of existing biomarkers and functional assays.
Implementation Method 1
antibodies that each specifically bind to a MCL-1 and BIM heterodimer
Data Source
AI summary
The present disclosure relates to compositions and methods of determining cancer cell sensitivity to treatment using antibodies that detect heterodimers comprising Bcl-2 proteins selected from MCL-1 and BIM. The disclosure also provides methods for predicting a cancer patient's sensitivity to the cancer treatment.